[¹⁸F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study.

"DISCLOSURE David Chan was funded by the National Health and Medical Research Council of Australia (GNT1175788) and also reports honoraria from Ipsen, Novartis, and Camurus and research support from EMD Serono, outside the submitted work. Gopinath Gnanasegaran reports personal fees from Advanced Accelerator Applications, a Novartis company, and received honoraria for lectures outside the submitted work. Nick Pavlakis reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Merck Serono, Ipsen, Amgen, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Roche Pharma AG, Merck, Baxalta, and Specialised Therapeutics, outside the submitted work. Martyn Caplin reports personal fees from Ipsen, Novartis, AAA, Lexicon, and Pfizer and grants from AAA and Ipsen, outside the submitted work. Christos Toumpanakis reports personal fees from Ipsen, Novartis, and AAA and education grants from Ipsen, Novartis, and AAA, outside the submitted work. No other potential conflict of interest relevant to this article was reported."

"David Chan was funded by the National Health and Medical Research Council of Australia (GNT1175788) and also reports honoraria from Ipsen, Novartis, and Camurus and research support from EMD Serono, outside the submitted work. Gopinath Gnanasegaran reports personal fees from Advanced Accelerator Applications, a Novartis company, and received honoraria for lectures outside the submitted work. Nick Pavlakis reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Merck Serono, Ipsen, Amgen, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Roche Pharma AG, Merck, Baxalta, and Specialised Therapeutics, outside the submitted work. Martyn Caplin reports personal fees from Ipsen, Novartis, AAA, Lexicon, and Pfizer and grants from AAA and Ipsen, outside the submitted work. Christos Toumpanakis reports personal fees from Ipsen, Novartis, and AAA and education grants from Ipsen, Novartis, and AAA, outside the submitted work. No other potential conflict of interest relevant to this article was reported."